Patents by Inventor Guanguan Li

Guanguan Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200181146
    Abstract: Provided herein are alpha5-containing GABAA receptor agonists and pharmaceutical compositions and methods of treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders using them.
    Type: Application
    Filed: March 20, 2017
    Publication date: June 11, 2020
    Inventors: James M. Cook, Guanguan Li, Michael Ming-Jin Poe, Miroslav M. Savic, Etienne Sibille
  • Patent number: 10483269
    Abstract: A semiconductor device includes a semiconductor substrate, a first dielectric layer having a first thickness on the semiconductor substrate, a first opening having a first width in the first dielectric layer, a second dielectric layer having a second thickness disposed in a middle region of the first opening, and a third dielectric layer having a first portion and a second portion disposed on opposite sides of second dielectric layer. The first portion and the second portion have a second width smaller than the first width, and the third dielectric layer has a third thickness smaller than the first thickness and the second thickness.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: November 19, 2019
    Assignees: SEMICONDUCTOR MANUFACTURING INTERNATIONAL (SHANGHAI) CORPORATION, SEMICONDUCTOR MANUFACTURING INTERNATIONAL (BEIJING) CORPORATION
    Inventors: Peng Huang, Jun Li, Honggang Dai, Guanguan Gu
  • Publication number: 20190300534
    Abstract: Described herein are ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.
    Type: Application
    Filed: February 25, 2019
    Publication date: October 3, 2019
    Inventors: James M. Cook, Michael Ming-Jin Poe, Kashi Reddy Methuku, Guanguan Li
  • Patent number: 10259815
    Abstract: Described herein are ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: April 16, 2019
    Assignee: UWM Research Foundation, Inc.
    Inventors: James Cook, Michael Ming-Jin Poe, Kashi Reddy Methuku, Guanguan Li
  • Publication number: 20180065967
    Abstract: Described herein are ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.
    Type: Application
    Filed: March 18, 2016
    Publication date: March 8, 2018
    Inventors: James Cook, Michael Ming-Jin Poe, Kashi Reddy Methuku, Guanguan Li